Cargando…
Clinical role of brexpiprazole in depression and schizophrenia
Brexpiprazole, a serotonin–dopamine activity modulator, is the second D(2) partial agonist to come to market and has been approved for the treatment of schizophrenia and as an adjunctive treatment in major depressive disorder. With less intrinsic activity than aripiprazole at the D(2) receptor and h...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354524/ https://www.ncbi.nlm.nih.gov/pubmed/28331332 http://dx.doi.org/10.2147/TCRM.S94060 |